Our expanding knowledge of the molecular biology of malignancy,the related identification of therapeutically-important targets,and the subsequent development of systemic agents that inhibit criticalkinases and pathways, have all contributed to great excitement andprogress in cancer treatment. In kidney cancer alone—long considereda drug-resistant disease—over five agents have been approved bythe US Food and Drug Administration since 2005.  For more details, go to: http://jco.ascopubs.org/content/early/2013/09/03/JCO.2013.50.3466?cmpid=jco_pap_3Sep2013